NAKSHATRA to boost viral genomic surveillance and preparedness for future pandemics: ICMR NIV Director
By Shalini Bhardwaj
Pune (Maharashtra) [India], June 18 (ANI): The NAKSHATRA state-of-the-art initiative aims to revolutionise how genomic and bioinformatics data are processed, addressing limitations faced during the COVID-19 pandemic.
Speaking to ANI, ICMR-NIV Pune Director Dr Naveen Kumar, explaining about NAKSHATRA, said, 'A high-performance computing system has been launched. This is the first kind of facility for the sequence analysis or genomic surveillance of pathogens under the ICMR.'
He further said, 'So nowadays, many new COVID variants, viruses, or pathogens are being reported. Our resources were insufficient because analysing the millions of sequences in the public domain takes a lot of time. We were doing extensive sequence analysis using multiple strains, which used to take weeks.Now we can do the same work in 24-48 hours. It has increased the capability of our country for genomic surveillance, which will help us in pandemic preparedness.'
Developed under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM), the HPC facility forms the cornerstone of a new project titled 'High Performance Computing Next Generation Sequencing (NGS) Hub'. The initiative aims to revolutionize how genomic and bioinformatics data are processed, addressing limitations faced during the COVID-19 pandemic due to conventional computing infrastructure.
The commissioning of the NAKSHATRA HPC facility is not just a technological upgrade--it is a national investment in speed, precision, and preparedness. By enabling faster analysis of complex genomic data, the facility positions India to detect new disease threats sooner, respond to outbreaks more efficiently, and accelerate AI-driven vaccine and drug development. (ANI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
31 minutes ago
- Time of India
4 unusual symptoms of NB.1.8.1 COVID variant, which is spreading in the world
A new COVID-19 variant, NB.1.8.1 or 'Nimbus', is spreading globally, exhibiting unusual symptoms. Despite the scary-sounding symptoms, health authorities like the WHO and CDC continue to stress that the NB.1.8.1 variant doesn't cause more severe disease in most people. It is, however, highly transmissible—and that's what makes it a concern. A new COVID-19 variant named NB.1.8.1, or 'Nimbus', is making quiet but swift rounds across several parts of the world. It's not just the usual fatigue or fever that's troubling people; this time, it's something sharper, something more unexpected. While scientists confirm that this Omicron subvariant doesn't lead to more severe disease, what's catching global attention is its unusual presentation, symptoms that feel different from what earlier COVID waves showed. And that makes it even more important to know what signs to watch out for. Here are 4 surprising symptoms of the Nimbus variant that are creating a buzz among doctors and patients alike, along with the science behind what's real and what's just speculation. A sore throat that feels like razor blades Patients infected with the NB.1.8.1 variant have reported a sore throat so intense, they've likened it to 'swallowing glass' or 'razor blades.' Global health reports have confirmed that this sharp throat pain is indeed a defining symptom of the new variant. Unlike previous sore throats linked to Omicron or Delta, this one comes on fast and can be severely painful even with mild fever. This symptom may not indicate greater danger, but it does signal high infectivity. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Branded GLP-1 Medications: What Are Your Options? GoodRx Watch Now Undo The pain likely stems from the variant's increased ability to bind tightly to throat cells, making it a hotspot for early replication. Sudden loss of appetite One overlooked but increasingly reported sign is a sudden dip in appetite, even without nausea or stomach issues. This symptom isn't new to COVID-19, but in the case of Nimbus, it seems to come early and without other digestive complaints. It is suggested this could be due to inflammatory markers affecting the hypothalamus (the appetite control center in the brain), even before other symptoms surface. Loss of appetite and unexplained weight loss. A significant change in eating habits without any clear reason may be worth keeping an eye on, especially if paired with fatigue or body aches. Muscle aches in unusual areas Muscle pain isn't new, but in this wave, people have been experiencing soreness in odd spots—like the jaw, upper back, and even behind the ears. These aches could be linked to how this variant activates the immune system. NB.1.8.1 causes an early inflammatory reaction, especially in muscle groups that aren't usually affected by respiratory illnesses. It's not always full-body fatigue, sometimes, discomfort in specific muscles might be telling a bigger story. Irritating nasal congestion that lingers Persistent nasal stuffiness, described as 'never-ending congestion,' is another complaint that has stood out in NB.1.8.1 cases. Covid Is Back! U.S. Confirms New Chinese Variant Causing Surge; Lockdown In America, India Next? Is it different from a cold? Quite possibly. Patients have reported that usual decongestants don't work effectively, and the congestion feels heavier, sometimes lasting over a week. This could be due to longer viral shedding in the nasal passages caused by this specific subvariant. Unlike seasonal colds, this symptom tends to stay and can increase the risk of spreading the virus to others through sneezing or coughing. (This article is intended for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment) One step to a healthier you—join Times Health+ Yoga and feel the change
Hans India
an hour ago
- Hans India
ICMR's affordable test kits boost diagnosis of genetic blood disorders in India
New Delhi: Simple and affordable point-of-care (POC) test kits, developed by scientists at the Indian Council of Medical Research (ICMR), are enhancing the diagnosis of genetic blood disorders like Haemophilia A, von Willebrand disease (VWD) and sickle cell disease (SCD) in the country. Haemophilia A, VWD, and SCD are serious inherited bleeding disorders, which often go undiagnosed because the testing is expensive and only available at a few specialised hospitals. India bears a significant burden from Haemophilia A. Estimates suggest around 136,000 individuals are affected, but only a small fraction are diagnosed and registered. While the prevalence of VWD in India is estimated at 1 per 12,000 in some regions, limited studies suggest a 10 per cent prevalence among inherited bleeding disorders. In the case of SCD, the disease is particularly prevalent in India, especially among the tribal population (57 per cent), though it also affects non-tribals (43 per cent). 'We have now multiple tests that are made in India and can diagnose blood disorders. That is something we all should be proud of,' Dr Manisha Madkaikar, Director, ICMR-Centre for Research, Management, and Control of Haemoglobinopathies (CRMCH) in Chandrapur district of Maharashtra, told IANS. ICMR-National Institute of Immunohaematology (NIIH) developed a POC test kit for diagnosing Haemophilia A, VWD, which can also be used at primary health centres (PHCs), bringing diagnosis closer to the people who need it most. Notably, 'the POC test costs just Rs 582 per patient, while the current lab-based tests cost around Rs. 2,086. Using this kit could help detect over 83,000 undiagnosed cases,' Madkaikar said, adding that the kits can 'save the health system about Rs 42 crore -- three times cheaper than the current method'. These tests are being integrated into the national health programme at the PHC level in different states. 'Using the cost-effective POC kits at PHCs and other local health centres can help India find and treat bleeding disorders early, improve patient outcomes, and cut healthcare costs dramatically,' the senior scientist said. In addition, 'the World Federation for Hemophilia has also shown interest in procuring these tests for deployment in countries where the disease is prevalent,' Madkaikar said. Further, to support the fight against SCD, ICMR-NIIH in Mumbai and CRMCH in Chhattisgarh have been officially chosen by the government to test and approve new diagnostic kits. "So far, they have checked and approved 30 different kits, including simple tests that can be done on the spot (like finger-prick tests); lab-based tests like HPLC; and tests that detect the disease at the genetic level," said Madkaikar, adding that these test kits may play a key role in the national screening programme for SCD that targets a population of 7 crore in the country. While the initial manufacturer's quote for the diagnostic test was Rs 350 per test, a comprehensive analysis by ICMR determined that POC tests for sickle cell disease/trait among the high-risk population in India would be cost-effective if procured at Rs 100 per test or below. Subsequently, the new kits validated by ICMR-NIIH are priced below Rs 50 per test. 'When the national sickle cell elimination mission was to be launched, we had only two point of care tests, which were recommended under the nation, and both of them were paid outside, and the cost of that was nearly 350 rupees," Madkaikar said. "But now multiple indigenous companies have come up with their point of care test. We now have different tests, right from solubility to point-of-care to molecular -- all made in India and easily available," the scientist said.
Economic Times
an hour ago
- Economic Times
Newborn screening, early treatment can cut sickle cell anaemia mortality: ICMR study
Post-birth diagnosis resulting in early treatment can substantially improve the quality of life and reduce mortality in patients with sickle cell disease to less than five per cent from the reported 20-30 per cent, according to an ICMR study. As many as 63,536 newborns were tested over a five year period from 2019- 2024 as part of the study on Newborn Screening for Sickle cell Disease conducted by the National Institute of Immunohaematology in Mumbai under the India Council of Medical Research (ICMR) across seven centres in high prevalence areas of India. The study is yet to be published. The newborn screening program helps find out if a baby is born with Sickle Cell Disease (SCD), a serious inherited blood disorder, soon after birth, explained Dr Manisha Madkaikar, Director of ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Nagpur. "If not detected early, this disease can cause life-threatening problems like severe infections, anaemia (low blood levels), and even strokes in infants," she stressed. "Finding the disease early can save lives by allowing doctors to start treatment before problems begin," Dr Prabhakar Kedar, Scientist F, ICMR-NIIH , who is the principal investigator of the study, diagnosed early can be given preventive antibiotics (like penicillin) to avoid infections and get regular checkups and care from specialists, Dr Madkaikar said. Early detection also helps in getting important vaccines to protect against serious illnesses while parents can also be taught the signs of danger so they can act quickly. It also helps families and doctors plan long-term treatment, provides genetic counselling to the family, and increases awareness, reducing the number of future cases, Dr Madkaikar explained. This screening is especially important in tribal and high-risk areas of India, where many cases go undiagnosed, leading to early childhood deaths, Dr Kedar highlighted. "With screening, many of these deaths can be prevented," he said. During the study, 7,275 babies (11.4 per cent) were found to be carriers of the sickle cell gene. This means they don't have the disease but can pass it on to their children, Dr Kedar said, adding, 569 babies (0.9 per cent) were found to have babies were followed up for the confirmation of diagnosis, parents were counselled about SCD, preventive measures to be taken for or to avoid complications, and informed about prenatal diagnosis to avoid any further births of affected children in the family."The babies were given comprehensive care, including penicillin prophylaxis, folic acid supplementation, appropriate vaccinations and hydroxyurea therapy, as indicated. This resulted in reduction in mortality in these children to less than 5 per cent from the earlier reported mortality of 20-30 per cent," Dr Kedar said. This study shows that newborn screening works and can save lives, especially in places with a high number of cases like tribal areas, Dr Kedar said. This study was coordinated by Dr Harpreet Kaur, senior scientists at ICMR, Delhi. "By detecting Sickle Cell Disease early, babies can get timely care, live healthier lives, and families can be better prepared," Dr Kedar said. The seven centres which participated in the study are National Institute For Implementation Research on Non-Communicable Diseases in Jodhpur, Society for Education, Welfare and Action-Rural (SEWA -Rural) in Gujarat, the Nilgiris Adivasi Welfare Association (NAWA), Tamil Nadu, ICMR- National Institute for Research in Reproductive Health in Mumbai, ICMR-National Institute of Research in Tribal Health (NIRTH) in Jabalpur, ICMR-Regional Medical Research Centre, Bhubaneswar and ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Chandrapur. Of the total 63,536 newborns tested, 57 per cent belonged to tribal parents and rest from others, Dr Kedar informed. The aim of the study was also to understand the regional variability and role of genetic modifiers in sickle cell disease as well as to identify barriers for newborn screening implementation, he explained.
